Cibele Dantas Ferreira Marques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cibele Dantas Ferreira Marques has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Elisa de Carvalho
Hospital da Criança de Brasília Brasília Brazil
4 shared publications - Gilda Porta
Hepatology and Liver Transplantation Hospital Sírio‐Libanês and Hospital Samaritano São Paulo Brazil
4 shared publications - Irene Kazue Miura
Hepatology and Liver Transplantation Hospital Sírio‐Libanês and Hospital Samaritano São Paulo Brazil
4 shared publications - Maria Angela Bellomo-Brandão
Universidade Estadual de Campinas, Brazil
4 shared publications - Regina Sawamura
Universidade de São Paulo (USP), Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (FMRP), Departamento de Puericultura e Pediatria, Ribeirão Preto, SP, Brazil
4 shared publications - Adriana Maria Alves de Tommaso
Universidade Estadual de Campinas, Brazil
3 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (3) , 101522
Biliary Atresia: advances and challenges in early diagnosis and management
- 10 March 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (3) , 101522
Open AccessBiliary Atresia: advances and challenges in early diagnosis and management
- Open Access
- 9 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1591-1600
Hepatic Glycogen Storage Diseases in Brazil: A Multicenter Study
To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (12 IIIa, 1 IIIb), 1 (0.8%) type IV, 6 (4.5%) type VI, and 49 (37.1%) with type IX (28 IXa, 7 IXb, and 14 IXc). Type I patients presented earlier (4 months) and had more episodes of hypoglycemia at clinical presentation ( p < 0.001). Anthropometric data at admission revealed impaired growth, with a tendency toward short stature across the groups (median −2.06, −1.89, and −1.96 among type I, III, and IX respectively). The median body mass index (BMI) z ‐scores at admission for all three types were above +1. Only patients with type IX demonstrated significant improvement in height ( p = 0.007) and BMI ( p = 0.020) z ‐scores during follow‐up. Regarding laboratory tests, significant decreases were observed in total cholesterol, triglycerides, venous lactate and aminotransferases in patients with types I and IX. Hepatic GSDs are heterogeneous diseases. There is a significant height impairment with a troublesome trend to overweight and obesity, especially in type I. Although there is improvement in aminotransferases, cholesterol, and triglycerides with follow‐up, adherence to treatment remains a challenge.
- 9 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1591-1600
Open AccessHepatic Glycogen Storage Diseases in Brazil: A Multicenter Study
To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (12 IIIa, 1 IIIb), 1 (0.8%) type IV, 6 (4.5%) type VI, and 49 (37.1%) with type IX (28 IXa, 7 IXb, and 14 IXc). Type I patients presented earlier (4 months) and had more episodes of hypoglycemia at clinical presentation ( p < 0.001). Anthropometric data at admission revealed impaired growth, with a tendency toward short stature across the groups (median −2.06, −1.89, and −1.96 among type I, III, and IX respectively). The median body mass index (BMI) z ‐scores at admission for all three types were above +1. Only patients with type IX demonstrated significant improvement in height ( p = 0.007) and BMI ( p = 0.020) z ‐scores during follow‐up. Regarding laboratory tests, significant decreases were observed in total cholesterol, triglycerides, venous lactate and aminotransferases in patients with types I and IX. Hepatic GSDs are heterogeneous diseases. There is a significant height impairment with a troublesome trend to overweight and obesity, especially in type I. Although there is improvement in aminotransferases, cholesterol, and triglycerides with follow‐up, adherence to treatment remains a challenge.
- Open Access
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (4) , 419-427
Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (4) , 419-427
Open AccessAutoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- Open Access
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (4) , 419-427
Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (4) , 419-427
Open AccessAutoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes